Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 19;19(5):21.
doi: 10.1007/s11892-019-1143-4.

The Interconnection Between Immuno-Metabolism, Diabetes, and CKD

Affiliations
Review

The Interconnection Between Immuno-Metabolism, Diabetes, and CKD

Fabrizia Bonacina et al. Curr Diab Rep. .

Abstract

Purpose of review: Metabolic reprogramming is increasingly recognized as an essential trait of functional activation of immune cells. Here, we describe the link between immuno-metabolism, diabetes, and diabetic nephropathy.

Recent findings: Crosstalk between cellular metabolic functions and immune activation occurs when plasma levels of glucose, triglycerides, and free fatty acids increase, thus promoting systemic low-grade inflammation that further boosts the development of metabolic complications. In the long run, this settles an "apparent paradox," where, despite excessive inflammation, the immune system is suppressed, further promoting progression to end-stage renal disease (ESRD) and predisposing to premature deaths from infections and cardiovascular diseases. Reviewing the effects of diabetes treatments on immuno-inflammatory responses suggests that the benefit of these drugs might extend beyond the simple control of glucose homeostasis. Hyperglycemia and dyslipidemia correlate with enhancement of the immuno-inflammatory response that can promote and worsen metabolic diseases and support the progression toward ESRD. The identification of cellular checkpoints that modulate the immuno-metabolic machinery of immune cells opens new venues for metabolic drugs.

Keywords: Diabetes; Immune response; Kidney disease; Metabolism.

PubMed Disclaimer

References

    1. Front Endocrinol (Lausanne). 2013 Jan 22;3:179 - PubMed
    1. Cell Metab. 2017 Feb 7;25(2):412-427 - PubMed
    1. Nat Immunol. 2013 May;14(5):489-99 - PubMed
    1. Cell Metab. 2017 Mar 7;25(3):506-521 - PubMed
    1. Nat Med. 2017 Sep;23(9):1036-1045 - PubMed

LinkOut - more resources